Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Open access
Yagi, Shusuke, Hirata, Yukina, Ise, Takayuki, Kusunose, Kenya, Yamada, Hirotsugu, Fukuda, Daiju, Salim, Hotimah Masdan, Maimaituxun, Gulinu, Nishio, Susumu, Takagawa, Yuriko, Hama, Saori, Matsuura, Tomomi, Yamaguchi, Koji, Tobiume, Takeshi, Soeki, Takeshi, Wakatsuki, Tetsuzo, Aihara, Ken-ichi, Akaike, Masashi, Shimabukuro, Michio, Sata, Masataka · 2017 · Diabetology & Metabolic Syndrome

Abstract

BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. CONCLUSION: Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13098-017-0275-4

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 179

Metadata

Authors
Yagi, S., Hirata, Y., Ise, T., Kusunose, K., Yamada, H., Fukuda, D., Salim, H. M., Maimaituxun, G., Nishio, S., Takagawa, Y., Hama, S., Matsuura, T., Yamaguchi, K., Tobiume, T., Soeki, T., Wakatsuki, T., Aihara, K.-I., Akaike, M., Shimabukuro, M., & Sata, M.
Venue
Diabetology & Metabolic Syndrome
Published
2017-10-04
Volume
9
Issue
1
Pages
78-78
ISSN
1758-5996 (ISSN-L)
OpenAlex
W2764144227
Cited by
179
References
5
FWCI
8.70
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1186/s13098-017-0275-4
The paper
Yagi, S., Hirata, Y., Ise, T., Kusunose, K., Yamada, H., Fukuda, D., Salim, H. M., Maimaituxun, G., Nishio, S., Takagawa, Y., Hama, S., Matsuura, T., Yamaguchi, K., Tobiume, T., Soeki, T., Wakatsuki, T., Aihara, K.-I., Akaike, M., Shimabukuro, M., & Sata, M. (2017). Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-017-0275-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.